Acid phosphatase is alysozomal enzyme1 of molecular weight 13 400 to greater than 200 000.2 Acid phosphatase activity is demonstrable in various tissues, especially prostate where this knowledge is applied in the diagnosis of metastatic carcinoma of prostatic origin. Other tissues rich in acid phosphatase include liver,2 platelets,3 bone and red blood cells,' and mammary epithelium.1 Apart from prostatic malignancy, other conditions may have associated increased activities of serum acid phosphatase including thrombocythaemia,3-' multiple myeloma and metastatic pancreatic carcinoma,5 Gaucher's disease," 6 leukaemia, Paget's disease, renal disease and liver disease,6 and carcinoid tumour of rectum.7 Raised serum acid phosphatase has also been reported in bronchogenic carcinoma.68 Our index case, which was erroneously diagnosed as metastatic carcinoma of prostate mainly on the basis of raised TAcP activities, proved at necropsy to be a case of widely disseminated bronchogenic oat cell carcinoma with only benign hyperplastic changes in the prostate gland. This finding prompted us to explore the significance of serum acid phosphatase activities in patients with lung cancer. Twenty-five cases are presented and analysed biochemically and immuno-*Present address: Department of Pathology, Royal Infirmary, Glasgow G4 OSF. Accepted for publication 11 March 1981 histochemically. These include our index case (No 11 in this series) and all were studied with emphasis on tumour morphology, liver function, bone metabolism, platelet count, and haemolysis.
Material and methods
Twenty-five consecutive cases of lung cancer were studied. They were all newly diagnosed cases and all had full routine investigations including full blood count, urea and electrolytes, urinalysis, chest x-ray examination, and sputum cytology. Serum acid phosphatase (AcP) activity was measured in all 25 cases. The total serum acid phosphatase activity (TAcP) was the only estimation in five cases, otherwise both TAcP and the NPAcP fraction (tartrate-stable) were measured. The five cases in which TAcP alone was measured each gave results within the normal reference range. Nine of the remaining 16 cases (36% of total number studied) had raised TAcP values. Of these nine cases, all AcP activities were mostly tartrate-stable (NPAcP). Five of the cases were oat-cell carcinomas (56 %), two were epidermoid carcinomas (22 %), one was a primary lung sarcoma (11 %), and one was a metastatic tumour of undetermined origin (11 %). Because of the small numbers involved, statistical analysis of these figures was not carried out. It is apparent, however, that raised serum NPAcP activity does not correlate with tumour morphology. It is also noteworthy that three of the nine patients with raised serum NPAcP were women (see Table 1 ).
TISSUE SECTIONS
Tissue sections from 15 cases were stained for AcP by the indirect immunoperoxidase technique. All 15 available tumours were negative in the first run and this finding was confirmed in the second run. The control tissues stained positively in each run, thereby confirming activity of the antiserum. Suitability of the antiserum was confirmed by positive staining of red blood cells and macrophages in the tumour sections. These findings were interpreted as indicating that the tumour cells themselves were not the source of the raised serum AcP observed. Seven further cases studied by immunohistochemistry did not contain any tumour tissue when the blocks were cut. There was no tissue available for study from three cases (Nos 15, 16, and 17 in the Tables). Of the other cases from which tumour tissue was not available in the blocks for immunohistochemistry, cases 4 and 5 had raised serum activities of NPAcP. This reduced the number of cases with raised serum NPAcP studied histochemically to seven. The remainder of this study was devoted to correlation of raised serum NPAcP in lung cancer patients with tests of function of other tissues (see Tables 1&2). LIVER Liver function tests were carried out in all 25 cases in this study. Of the nine cases with raised serum NPAcP activities, complete liver function tests were available in five, but abnormalities were apparent in all nine cases (100%). These ranged from minor disturbances of individual parameters to severe upset in the full range of tests. However, similar degrees of abnormality were noted in 14 of the 16 Other tissues known to contain AcP (apart from prostate) include liver, bone, red blood cells, and platelets. It was attempted, on the basis of this knowledge, to correlate the observed raised serum activities of NPAcP in our nine patients with biochemical evidence of dysfunction of these tissues. However, no clear association could be found between liver dysfunction, haemolysis or bone metabolism and raised serum NPAcP activity. Therefore, serum NPAcP activity cannot be held to reflect the possible pre-sence of tumour metastases in these organs (liver or bone). It was considered that raised serum alkaline phosphatase activity might indicate hepatic metastasis of lung cancer, but even if this assumption were correct, then from our study it would clearly have to precede any rise in serum NPAcP and so invalidate the latter as a screening test for early hepatic metastasis.
One aside noted was the association of raised serum NPAcP activities in two of four patients with raised platelet counts. The numbers involved here are too small to allow conclusions to be drawn, but if this association were confirmed in a larger series, it could add to our knowledge of thrombosis and embolism in patients with malignant disease.
The main points to emerge from this series, however, are (1) 
